Stoke Therapeutics Inc (STOK)
15.35
-0.75
(-4.66%)
USD |
NASDAQ |
May 21, 16:00
15.36
+0.02
(+0.10%)
After-Hours: 20:00
Stoke Therapeutics Free Cash Flow: -85.74M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -85.74M |
| December 31, 2023 | -82.68M |
| September 30, 2023 | -84.59M |
| June 30, 2023 | -91.03M |
| March 31, 2023 | -89.00M |
| December 31, 2022 | -35.83M |
| September 30, 2022 | -29.51M |
| June 30, 2022 | -20.38M |
| March 31, 2022 | -16.12M |
| December 31, 2021 | -68.11M |
| September 30, 2021 | -62.67M |
| Date | Value |
|---|---|
| June 30, 2021 | -58.85M |
| March 31, 2021 | -52.23M |
| December 31, 2020 | -43.27M |
| September 30, 2020 | -43.02M |
| June 30, 2020 | -40.51M |
| March 31, 2020 | -37.45M |
| December 31, 2019 | -32.69M |
| September 30, 2019 | -25.53M |
| June 30, 2019 | -20.46M |
| March 31, 2019 | -16.51M |
| December 31, 2018 | -11.90M |
Free Cash Flow Range, Past 5 Years
-91.03M
Minimum
Jun 2023
-16.12M
Maximum
Mar 2022
-50.98M
Average
-43.14M
Median
Free Cash Flow Benchmarks
| NeuBase Therapeutics Inc | -14.85M |
| iBio Inc | -18.67M |
| Actinium Pharmaceuticals Inc | -39.72M |
| Lixte Biotechnology Holdings Inc | -3.811M |
| Fate Therapeutics Inc | -139.78M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -24.57M |
| Cash from Investing (Quarterly) | 9.988M |
| Cash from Financing (Quarterly) | 1.717M |
| Free Cash Flow Per Share (Quarterly) | -0.5315 |
| Free Cash Flow to Equity (Quarterly) | -24.58M |
| Free Cash Flow Yield | -12.44% |